On July 17, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) announced that S-INFINITY Co., Ltd. (“S-INFINITY”), a subsidiary of Fosun Pharma, has recently initiated the Phase 1b clinical trial on its self-developed new drug, XH-S004 (hereinafter the “New Drug”), for the treatment of chronic obstructive pulmonary disease (COPD) in China (excluding Hong Kong SAR, Macau SAR, and Taiwan region).

XH-S004 is a small molecule oral DPP-1 inhibitor independently developed by Fosun Pharma, which is intended to be used for the treatment of chronic obstructive pulmonary disease (COPD), non-cystic fibrosis bronchiectasis and others. Another indication of XH-S004 for the treatment of non-cystic fibrosis bronchiectasis is under Phase II clinical trial stage in Mainland China.

The primary goals of stable-phase COPD treatment are to alleviate symptoms, reduce acute exacerbations, and slow disease progression. Current standard treatments, primarily bronchodilators and inhaled corticosteroids, can relieve symptoms to a certain extent but have limited efficacy in preventing acute exacerbations or slowing disease progression. The most common type of COPD is non-type 2/neutrophilic inflammation, accounting for about 60-80%. Over the past two decades, only one new‑mechanism drug targeting eosinophilic type 2 inflammation in COPD has been approved in China. Consequently, there remain significant unmet medical needs for therapies that effectively control neutrophilic inflammation in COPD patients.

XH-S004 exerts its effect primarily on neutrophils, by inhibiting DPP-1 and neutrophil‑activated serine proteases to reduce chronic inflammatory responses and associated airway damage in COPD. It is expected to decrease COPD’s acute exacerbations and slow disease progression, potentially transforming the treatment landscape for chronic obstructive pulmonary disease. To date, no small-molecule oral inhibitor with the same molecular mechanism has been approved for marketing globally.

***

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; SSE: 600196, HKEX: 02196) is a leading innovation-driven global healthcare company operating in the fields of pharmaceuticals, medical devices & diagnostics, and healthcare services. Through its strategic alliance with Sinopharm Group Co., Ltd., Fosun Pharma further extends its capabilities in pharmaceutical commerce.

Over the past 30 years since its establishment, Fosun Pharma has maintained deep roots in China while strategically expanding its global presence. The company has been actively implementing its “4IN” strategy - Innovation, Internationalization, Intelligentization, and Integration, with core business operations now spanning major overseas markets including the United States, Europe, Africa, India, and Southeast Asia. At present, Fosun Pharma has established an open and globally integrated pharmaceutical R&D ecosystem, focusing on core therapeutic areas including oncology (solid tumors and hematologic malignancies) and Immune-inflammatory disorders. The company is strategically enhancing its technological leadership in antibody/ADC platforms, cell therapies, and small molecule development, while collaborating with industry funds to pioneer next-generation modalities such as radiopharmaceuticals, RNA therapeutics, gene editing, and AI-powered drug discovery. This multidimensional approach accelerates the translation of innovative therapies into clinical practice, systematically addressing critical unmet medical needs worldwide.

Looking ahead, Fosun Pharma remains anchored in its core values of “Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership”. By advancing its global innovation engine and operational excellence, the company strives to be a global leader to integrate pharmaceutical and healthcare innovations, creating better health for families worldwide.

For more information, please visit our official website:www.fosunpharma.com